Status:
COMPLETED
Dexmedetomidine and Outcomes of Cardiac Surgery (DOCS)
Lead Sponsor:
Xijing Hospital
Conditions:
Heart Valve Diseases
Coronary Artery Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
Cardiac surgery is associated with a high risk of cardiovascular and other complications. The investigators hypothesized that perioperative infusion of dexmedetomidine may reduce the incidence of comp...
Detailed Description
There are about 694,000 open-heart surgeries performed in US each year. The major complication rates for valve plus coronary artery bypass graft (CABG) procedure are as high as 30.1% in Society of Tho...
Eligibility Criteria
Inclusion
- Provide written informed consent
- Are \> 18 years of age
- Elective cardiac surgery with CPB, when the surgeon plans to do valve and/or CABG surgery
Exclusion
- Emergent cardiac surgery
- Other than CABG and/or Valve surgery
- off-pump or robotic surgery
- Surgery requiring deep hypothermic circulatory arrest or involving the thoracic aorta
- Life expectancy \< 1 year
- Preop severe liver or renal dysfunction, with replacement therapy required
- Patients with IABP or with cardiogenic shock
- Severe dehydrate or dystrophia or Hb \< 10 g/dl
- History of any alpha-2 receptor agonists allergy.
- Refuse to provide written informed consent
- Diagnosed with mental illness
Key Trial Info
Start Date :
April 9 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2018
Estimated Enrollment :
1100 Patients enrolled
Trial Details
Trial ID
NCT02237495
Start Date
April 9 2014
End Date
March 1 2018
Last Update
July 8 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Xijing Hospital
Xi'an, Shaanxi, China, 710032